Journal of Ginseng Research

  • 제41권2호
  • /
  • Pages.222-226
  • /
  • 2017
  • /
  • 1226-8453(pISSN)
  • /
  • 2093-4947(eISSN)
고려인삼학회 (The Korean Society of Ginseng)
권호 표지
DOI QR코드

DOI QR Code

Effect of Korean Red Ginseng intake on the survival duration of human immunodeficiency virus type 1 patients

  • Cho, Young-Keol (Department of Microbiology, University of Ulsan College of Medicine) ;
  • Kim, Jung-Eun (Department of Microbiology, University of Ulsan College of Medicine)
  • 투고 : 2016.08.25
  • 심사 : 2016.12.08
  • 발행 : 2017.04.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Long-term ginseng intake can increase longevity in healthy individuals. Here, we examined if long-term treatment with Panax ginseng Meyer (Korean Red Ginseng, KRG) can also enhance survival duration (SD) in patients with human immunodeficiency virus type 1 (HIV-1) infection. Methods: We retrospectively analyzed 252 HIV-1 patients diagnosed from 1986 to 2013 prior to the initiation of antiretroviral therapy. Overall, 162 patients were treated with KRG ($3,947{\pm}4,943g$) for $86{\pm}63$ mo. The effects of KRG on SD were analyzed according to the KRG intake level and the length of the follow-up period. Results: There were significant correlations between the total amount of KRG and SD in the KRG intake group (r = 0.64, p < 0.0001) as well as between total amount of KRG and mean annual decrease in $CD4^+$ T-cell count in all 252 patients (r = -0.17, p < 0.01). The annual decrease in $CD4^+$ T-cell count (change in $cells/{\mu}L$) was significantly slower in KRG-treated patients than in patients receiving no KRG ($48{\pm}40$ vs. $106{\pm}162$; p < 0.001). The SD (in months) was also significantly longer in the KRG group than in the no-KRG group ($101{\pm}64$ vs. $59{\pm}40$, p < 0.01). Conclusion: KRG prolongs survival in HIV-1 patients, possibly by slowing the decrease in $CD4^+$ T-cell count.

키워드

참고문헌

  1. Perelson AS, Neumann AU, Markowitz M, Leonard JM. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6. https://doi.org/10.1126/science.271.5255.1582
  2. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35. https://doi.org/10.1056/NEJM199302043280508
  3. Palella Jr FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60. https://doi.org/10.1056/NEJM199803263381301
  4. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fatkenheuer G, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795-807. https://doi.org/10.1056/NEJMoa1506816
  5. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016;530:51-6. https://doi.org/10.1038/nature16933
  6. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998;128:906-11. https://doi.org/10.7326/0003-4819-128-11-199806010-00008
  7. Roger M. Influence of host genes on HIV-1 disease progression. FASEB J 1998;12:625-32. https://doi.org/10.1096/fasebj.12.9.625
  8. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-91. https://doi.org/10.1126/science.270.5238.988
  9. GW1 Nelson, Kaslow R, Mann DL. Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci U S A 1997;94:9802-7. https://doi.org/10.1073/pnas.94.18.9802
  10. Oh MD, Kim SS, Kim EY, Lee S, Kim N, Park KY, Kim U, Kim T, Kim T, Choe K, et al. The frequency of mutation in CCR5 gene among Koreans. Int J STD AIDS 2000;11:266-7. https://doi.org/10.1258/0956462001915688
  11. Sung HS, Kang SM, Lee MS, Kim TG, Cho YK. Korean Red Ginseng slows depletion of CD4 T cells in HIV type 1-infected patients. Clin Diagn Lab Immunol 2005;12:497-501.
  12. Cho YK, Sung H, Kim TK, Lim J, Jung YS, Kang SM. Korean Red Ginseng significantly slows CD4 T cell depletion over 10 years in HIV-1 infected patients: association with HLA. J Ginseng Res 2004;28:173-82. https://doi.org/10.5142/JGR.2004.28.4.173
  13. Yun TK. Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci 2001;16(Suppl):S3-5. https://doi.org/10.3346/jkms.2001.16.S.S3
  14. Li CP, Li RC. An introductory note to ginseng. Am J Chin Med 1973;1:249-61. https://doi.org/10.1142/S0192415X73000279
  15. Singh VK, Agarwhal SS, Gupta BM. Immunomodulatory activity of Panax ginseng extract. Planta Med 1984;50:462-5. https://doi.org/10.1055/s-2007-969773
  16. Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini F. Immunomodulatory effects of two extracts of Panax ginseng C. A. Meyer. Drugs Exp Clin Res 1990;16:537-42.
  17. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology 1997;35:229-35. https://doi.org/10.1016/S0162-3109(96)00125-7
  18. Lee SY, Jeong JJ, Eun SH, Kim DH. Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis. Eur J Pharmacol 2015;762:333-43. https://doi.org/10.1016/j.ejphar.2015.06.011
  19. Tan S, Yu W, Lin Z, Chen Q, Shi J, Dong Y, Duan K, Bai X, Xu L, Li J, et al. Antiinflammatory effect of ginsenoside Rb1 contributes to the recovery of gastrointestinal motility in the rat model of postoperative ileus. Biol Pharm Bull 2014;37:1788-94. https://doi.org/10.1248/bpb.b14-00441
  20. Yayeh T, Jung KH, Jeong HY, Park JH, Song YB, Kwak YS, Kang HS, Cho JY, Oh JW, Kim SK, et al. Korean Red Ginseng saponin fraction downregulates proinflammatory mediators in LPS stimulated RAW264. 7 cells and protects mice against endotoxic shock. J Ginseng Res 2012;36:263-9. https://doi.org/10.5142/jgr.2012.36.3.263
  21. Song X, Hu S. Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine 2009;6:4883-90.
  22. Cho YK, Kim YB, Choi BS, Cho YJ, Suh IS, Shin YO. The increase of T cell by Korean Red Ginseng in HIV-infected individuals. J Korean Soc Microbiol 1994;28:371-9.
  23. Cho YK, Kim YK, Shin YO, Cho YJ. Change of serum ${\beta}2$-microglobulin, p24 antigen and $CD4^{+}$ T lymphocyte in persons with HIV infection after azidothymidine treatment. Korean J Infect Dis 1993;25:211-20.
  24. Cho YK, Kim YK, Lee I, Choi MH, Shin YO. The effect of Korean Red Ginseng (KRG), zidovudine (ZDV), and the combination of KRG and ZDV on HIVinfected patients. Korean Soc Microbiol 1996;31:353-60.
  25. Cho YK, Lee HJ, Kim YB, Oh WI, Kim YK. Sequence analysis of C2/V3 region of HIV type 30 gp120 and its correlation with clinical significance; the effect of long-term intake of Korean Red Ginseng on env gene variation. J Korean Soc Microbiol 1997;32:611-23.
  26. Cho YK, Sung H, Lee HJ, Joo CH, Cho GJ. Long-term intake of Korean Red Ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed. Int Immunopharmacol 2001;1:1295-305. https://doi.org/10.1016/S1567-5769(01)00061-3
  27. Cho YK, Sung H, Ahn SH. Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in HIV type 1-infected patients in Korea. J Clin Microbiol 2002;40:1319-25. https://doi.org/10.1128/JCM.40.4.1319-1325.2002
  28. Sung HS, Jung YS, Kang MW. High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART. AIDS Res Hum Retroviruses 2007;23:1223-9. https://doi.org/10.1089/aid.2007.0008
  29. Yi SW, Sull JW, Hong JS, Linton JA, Ohrr H. Association between ginseng intake and mortality: Kangwha cohort study. J Altern Complement Med 2009;15:921-8. https://doi.org/10.1089/acm.2008.0296
  30. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B, Sieg SF, Teixeira-Johnson L, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010;6:e1000917. https://doi.org/10.1371/journal.ppat.1000917
  31. Cho A, Roh YS, Uyangaa E, Jong SP, Kim W, Lim KH, Kwon J, Eo SK, Lim CW, Kim B. Protective effects of red ginseng extract against vaginal herpes simplex virus infection. J Ginseng Res 2013;37:210-8. https://doi.org/10.5142/jgr.2013.37.210
  32. Cho Y, Sung H. Effect of Korean Red Ginseng on serum soluble CD8 in HIV-1-infected patients. J Ginseng Res 2007;31:175-80. https://doi.org/10.5142/JGR.2007.31.4.175
  33. Carpenter CC, Cooper DA, Fischl MA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000;83:381-90.

피인용 문헌

  1. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review vol.32, pp.5, 2017, https://doi.org/10.1002/ptr.6024
  2. Pharmacological effects of ginseng on infectious diseases vol.27, pp.5, 2017, https://doi.org/10.1007/s10787-019-00630-4
  3. Progress of Plant Medicine Derived Extracts and Alkaloids on Modulating Viral Infections and Inflammation vol.15, pp.None, 2017, https://doi.org/10.2147/dddt.s299120
  4. African and Asian Medicinal Plants as a Repository for Prospective Antiviral Metabolites Against HIV-1 and SARS CoV-2: A Mini Review vol.12, pp.None, 2021, https://doi.org/10.3389/fphar.2021.703837
  5. Korean traditional foods as antiviral and respiratory disease prevention and treatments: A detailed review vol.116, pp.None, 2021, https://doi.org/10.1016/j.tifs.2021.07.037